Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.

Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T, Matsuda K, Yasui-Furukori N, Nakagawa K, Ishitsu T, Saruwatari J.

PLoS One. 2015 Oct 20;10(10):e0141266. doi: 10.1371/journal.pone.0141266. eCollection 2015.

2.

Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.

Inoue Y, Ohtsuka Y; STP-1 Study Group.

Epilepsy Res. 2015 Jul;113:90-7. doi: 10.1016/j.eplepsyres.2015.03.012. Epub 2015 Apr 6.

PMID:
25986195
3.

Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy.

Tanamachi Y, Saruwatari J, Noai M, Kamihashi R, Soraoka H, Yoshimori Y, Ogusu N, Oniki K, Yasui-Furukori N, Ishitsu T, Nakagawa K.

Neuropsychiatr Dis Treat. 2015 Apr 7;11:1007-14. doi: 10.2147/NDT.S80898. eCollection 2015.

4.

Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.

Ogusu N, Saruwatari J, Nakashima H, Noai M, Nishimura M, Deguchi M, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagaswa K.

PLoS One. 2014 Nov 5;9(11):e111066. doi: 10.1371/journal.pone.0111066. eCollection 2014.

5.

ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts.

Sha'ari HM, Haerian BS, Baum L, Saruwatari J, Tan HJ, Rafia MH, Raymond AA, Kwan P, Ishitsu T, Nakagawa K, Lim KS, Mohamed Z.

Pharmacogenomics. 2014 Mar;15(4):459-66. doi: 10.2217/pgs.13.239.

PMID:
24624913
6.

Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction.

Saruwatari J, Yoshida S, Tsuda Y, Okada Y, Ogusu N, Yoshida K, Oniki K, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagawa K.

Pharmacogenet Genomics. 2014 Mar;24(3):162-71. doi: 10.1097/FPC.0000000000000030.

PMID:
24384557
7.

Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.

Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K, Tsuda Y, Nishimura M, Nagata R, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagawa K.

Ther Drug Monit. 2014 Jun;36(3):302-9. doi: 10.1097/FTD.0000000000000015.

PMID:
24345815
8.

Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases.

Saruwatari J, Deguchi M, Yoshimori Y, Noai M, Yoshida S, Ogusu N, Oniki K, Yoshida S, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagawa K.

Epilepsy Res. 2012 Mar;99(1-2):183-6. doi: 10.1016/j.eplepsyres.2011.10.033. Epub 2011 Nov 25.

PMID:
22119635
9.

Atrioventricular block and diastolic dysfunction in a patient with Sanfilippo C.

Misumi I, Chikazawa S, Ishitsu T, Higuchi S, Shimazu T, Ikeda C, Uchino M, Shibata Y, Ebihara K, Akahoshi R.

Intern Med. 2010;49(21):2313-6. Epub 2010 Nov 1.

10.

Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Saruwatari J, Ishitsu T, Nakagawa K.

Pharmaceuticals (Basel). 2010 Aug 20;3(8):2709-2732. Review.

11.

Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.

Okada Y, Seo T, Ishitsu T, Wanibuchi A, Hashimoto N, Higa Y, Nakagawa K.

Ther Drug Monit. 2008 Aug;30(4):540-3. doi: 10.1097/FTD.0b013e31817d842a.

PMID:
18641551
12.

Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K.

Br J Clin Pharmacol. 2008 Aug;66(2):304-7. doi: 10.1111/j.1365-2125.2008.03203.x. Epub 2008 Apr 11.

13.

Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.

Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K.

Pharmacogenomics. 2008 May;9(5):527-37. doi: 10.2217/14622416.9.5.527.

PMID:
18466100
14.

ABCC2 haplotype is not associated with drug-resistant epilepsy.

Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K.

J Pharm Pharmacol. 2008 May;60(5):631-5. doi: 10.1211/jpp.60.5.0009.

PMID:
18416940
15.

Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.

Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K.

J Pharm Pharmacol. 2008 Feb;60(2):267-72. doi: 10.1211/jpp.60.2.0017.

PMID:
18237476
16.
17.

Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.

Ueda K, Ishitsu T, Seo T, Ueda N, Murata T, Hori M, Nakagawa K.

Pharmacogenomics. 2007 May;8(5):435-42.

PMID:
17465707
18.

Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.

Goto S, Seo T, Murata T, Nakada N, Ueda N, Ishitsu T, Nakagawa K.

Ther Drug Monit. 2007 Feb;29(1):118-21.

PMID:
17304159
19.

ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K.

Pharmacogenomics. 2006 Jun;7(4):551-61.

PMID:
16753003
20.

Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy.

Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, Ishitsu T.

Clin Pharmacol Ther. 2006 May;79(5):509-10. No abstract available.

PMID:
16678552

Supplemental Content

Loading ...
Support Center